cetrorelix 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
gonadotropin-releasing-hormone (GnRH) inhibitors, peptides 583 120287-85-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cetrotide
  • cetrorelix acetate
  • cetrorelix
LHRH antagonist
  • Molecular weight: 1431.06
  • Formula: C70H92ClN17O14
  • CLOGP: -3.09
  • LIPINSKI: 3
  • HAC: 31
  • HDO: 17
  • TPSA: 495.67
  • ALOGS: -5.31
  • ROTB: 38

Drug dosage:

DoseUnitRoute
0.25 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 8 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution) 0.39 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 11, 2000 FDA EMD SERONO INC
April 12, 1999 EMA MERCK EUROPE B.V.
April 20, 2006 PMDA NIPPON KAYAKU CO., LTD.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 824.28 56.34 119 621 3895 63484387
Premature ovulation 149.80 56.34 15 725 7 63488275
Blood luteinising hormone increased 135.23 56.34 16 724 93 63488189
Ascites 95.46 56.34 30 710 40698 63447584
Ovarian disorder 60.77 56.34 10 730 720 63487562
Abortion spontaneous 60.02 56.34 22 718 47173 63441109
Pelvic fluid collection 58.95 56.34 10 730 866 63487416

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 852.41 67.81 114 474 3457 79740343
Premature ovulation 124.42 67.81 12 576 7 79743793
Blood luteinising hormone increased 95.53 67.81 12 576 199 79743601
Ascites 86.87 67.81 29 559 75533 79668267

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01CC02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
HYPOTHALAMIC HORMONES
Anti-gonadotropin-releasing hormones
FDA PE N0000008638 Decreased GnRH Secretion
FDA MoA N0000175084 Gonadotropin Releasing Hormone Receptor Antagonists
MeSH PA D005300 Fertility Agents, Female
MeSH PA D006727 Hormone Antagonists
MeSH PA D012102 Reproductive Control Agents
FDA EPC N0000175839 Gonadotropin Releasing Hormone Receptor Antagonist
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:59229 GnRH antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Prevention of premature ovulation during controlled ovarian stimulation indication 732970000
Premature Luteinizing Hormone Surges indication
Prevention of premature ovulation indication
Acute nephropathy contraindication 58574008
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.09 acidic
pKa3 12.45 acidic
pKa4 13.01 acidic
pKa5 13.29 acidic
pKa6 13.37 acidic
pKa7 13.67 acidic
pKa8 13.71 acidic
pKa9 10.75 Basic
pKa10 5.35 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.25MG BASE/VIAL CETRORELIX ACETATE TEVA PHARMS INC A215737 Aug. 12, 2022 RX POWDER SUBCUTANEOUS April 22, 2023 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR ANTAGONIST Ki 8.80 CHEMBL CHEMBL
Lutropin-choriogonadotropic hormone receptor GPCR WOMBAT-PK

External reference:

IDSource
D01685 KEGG_DRUG
130143-01-0 SECONDARY_CAS_RN
259338 RXNORM
C0209366 UMLSCUI
CHEBI:59224 CHEBI
CHEMBL1200490 ChEMBL_ID
CHEMBL2103735 ChEMBL_ID
DB00050 DRUGBANK_ID
C062876 MESH_SUPPLEMENTAL_RECORD_UI
1190 IUPHAR_LIGAND_ID
6661 INN_ID
OON1HFZ4BA UNII
25074887 PUBCHEM_CID
15671 MMSL
362200 MMSL
37942 MMSL
d04706 MMSL
007799 NDDF
007800 NDDF
326083001 SNOMEDCT_US
395906005 SNOMEDCT_US
412114000 SNOMEDCT_US
4021277 VANDF
4024232 VANDF

Pharmaceutical products:

None